Shorted
Avecho Biotechnology logo
AVE
Pharmaceuticals, Biotechnology & Life Sciences

Avecho Biotechnology

Short interest
0.00%
−0.12 pp 30d
as of 10 Feb 2025
Reported shorts
29.6K
Shares on issue
3.169B

Avecho Biotechnology (AVE) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
7 Oct

Where Does Avecho (ASX:AVE) Take Its CBD Sleep Capsule Next?

Highlights Avecho Biotechnology has outlined plans to engage with US and European regulators after its Phase III insomnia trial passed an interim analysis. The independent data monitoring board backed continuing the trial to full enrolment, with no serious adverse events recorded at the interim stage. Australian commercial rights are already licensed to Sandoz, and the company is pursuing further regional licensing deals. Avecho Biotechnology (ASX:AVE) is preparing to take its cannabidiol sle...

Continue reading
Kalkine
Neutral
25 Sept

What Does a Rival CBD Push Mean for Avecho (ASX:AVE)?

Highlights Unlisted rival seeks a fast-track route for its CBD tablet Late-stage insomnia study is in its final recruitment phase The prize is the first registered pharmacy CBD product Avecho Biotechnology (ASX:AVE) is back in focus this week after an unlisted Sydney rival said it would seek fast-track registration for its own cannabidiol tablet despite missing an efficacy target, sharpening attention on the race to put the first registered CBD medicine on Australian pharmacy shelves. The Riv...

Continue reading
Kalkine
Neutral
11 Sept

Is Avecho (ASX:AVE) Nearing an Over-the-Counter Milestone?

Highlights An independent monitoring board cleared the insomnia study to continue to full enrolment. Patent allowances in America and Europe cover the soft-gel capsule formulation. Australian rights were licensed to a large international generics manufacturer. Avecho Biotechnology (ASX:AVE) is running what has been described as the largest cannabidiol insomnia trial in the world, and an independent data monitoring board cleared the study to continue to full enrolment after reviewing interim r...

Continue reading
Kalkine
Neutral
31 Aug

Is Avecho (ASX:AVE) Changing the Cannabis Stocks Debate?

Highlights Avecho Biotechnology licensed its delivery technology into the United States recreational cannabis market. The agreement pairs an Australian drug delivery platform with an offshore consumer product partner. A cannabidiol capsule programme continues alongside the licensing arrangement. For Australian equities, Avecho (ASX:AVE) now sits at an important junction between sector conditions, company delivery and changing market expectations. Avecho Biotechnology (ASX:AVE) has taken a dif...

Continue reading
Kalkine
Neutral
27 Aug

What Could Shape Avecho (ASX:AVE) as Its Next Clinical Phase Develops?

Highlights Avechos funding position provides breathing room as its pivotal insomnia program moves through a critical late-stage development period. A positive interim review allowed the Phase III study to continue at its planned enrolment, keeping the clinical pathway intact. Commercial partnerships, regulatory preparation and intellectual-property expansion are becoming increasingly important alongside trial execution. Australias biotechnology sector often turns on the balance between scient...

Continue reading
Kalkine
Neutral
21 May

Avecho Biotechnology Advances Insomnia Program Momentum

Highlights Avecho advances key insomnia trial stage CBD therapy program moves toward analysis Australian OTC pathway remains in focus Avecho Biotechnology has reached another important milestone in its insomnia treatment program, moving closer to clinical analysis and broader regulatory progress in Australia’s evolving cannabidiol market. Avecho Biotechnology (ASX:AVE) has reached a significant stage in its clinical development journey after completing treatment requirements for t...

Continue reading
Kalkine
Neutral
7 May

Is Avecho Biotechnology (ASX:AVE) the Next ASX 300 Healthcare Stock in Focus?

Highlights Healthcare technology operations remained active across Australian equity markets. Pharmaceutical infrastructure and capital market activity shaped participation. Enterprise systems and digital healthcare technologies supported operations. Healthcare technology and pharmaceutical infrastructure activity remained active across Australian equities as operational systems and medical technologies shaped market participation. Australia’s healthcare and pharmaceutical technol...

Continue reading